Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors

• Main Authors: Tian Yu (Author), Xiangyu Liu (Author), Chi‐Yuan Wu (Author), Zhiyu Tang (Author), Hongwei Wang (Author), Patrick Schnell (Author), Ya Wan (Author), Kun Wang (Author), Lucy Liu (Author), Yuying Gao (Author), Srikumar Sahasranaman (Author), Nageshwar Budha (Author)
• Format: Book
• Published: Wiley, 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Tislelizumab, an anti‐programmed cell death protein 1 monoclonal antibody, has demonstrated improved survival benefits over standard of care for multiple cancer indications. We present the clinical rationale and data supporting tislelizumab dose recommendation in patients with advanced tumo...